Great Point Partners’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Great Point Partners’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-547,712	Closed	-$3.3M	–	44
2019 Q2	$3.3M	Sell	547,712 -1,850,697	-77%	-$17.7M	0.37%	28
2019 Q1	$32.1M	Hold	2,398,409	–	–	3.18%	15
2018 Q4	$22.3M	Buy	2,398,409 +750,656	+46%	+$8.93M	2.82%	15
2018 Q3	$22.9M	Buy	1,647,753 +387,753	+31%	+$5.77M	3.57%	15
2018 Q2	$19.9M	Buy	1,260,000 +391,900	+45%	+$6.84M	2.76%	16
2018 Q1	$14.9M	Buy	+868,100	New	+$16.9M	2.21%	18
2017 Q2	–	Sell	-155,265	Closed	-$5.61M	–	49
2017 Q1	$5.61M	Buy	+155,265	New	+$6.84M	1.11%	25
2016 Q2	–	Sell	-575,000	Closed	-$23.4M	–	44
2016 Q1	$23.4M	Buy	575,000 +5,342	+0.9%	+$184K	8.38%	2
2015 Q4	$23.6M	Sell	569,658 -657,127	-54%	-$22M	9.92%	2
2015 Q3	$18.9M	Buy	1,226,785 +548,190	+81%	+$11.8M	7.47%	2
2015 Q2	$16.9M	Buy	+678,595	New	+$15.1M	6.57%	4

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's FPRX Position: Q3 2019 in Review

Great Point Partners sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2019, closing a stake of 547,712 shares — an estimated $3.3M sold.

Great Point Partners first reported a position in FPRX in Q2 2015 and held it in 11 quarters. The position peaked at $32.1M in Q1 2019. 103 funds tracked by Wall St. Rank hold FPRX as of Q3 2019.

Great Point Partners reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Great Point Partners sold 547,712 Five Prime Therapeutics, Inc. shares in Q3 2019, an estimated $3.3M.
Great Point Partners first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 11 quarters.
Great Point Partners's Five Prime Therapeutics, Inc. position peaked at $32.1M in Q1 2019.
103 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2019.

Based on Great Point Partners's 13F filing for Q3 2019, filed 15 Nov 2019.